Co-Diagnostics Inc. (CODX)
CODX trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1692415/000149315226014158/0001493152-26-014158-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CODX on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001692415 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | UT |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $622K |
| Net income | -$46.9M |
| Operating income | -$50.2M |
| Net margin | -7533.6% |
| Operating margin | -8058.8% |
| Revenue growth | -84.1% |
| Cash | $11.9M |
| Total assets | $24.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued. 7 The condensed consolidated financial statements as of September 30, 2026 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months after these fin" | 10-Q 2026-11-10 |
| Cash and burn | $715K cash; operating cash flow -$6.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 10,512,190 (2026-11-06); 60,892,582 a year earlier; 30,580,904 three years earlier. 1y figure adjusted for split (1-for-30 overall); 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2026-01-02 | Source 2026-01-02 |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-07-27 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-13 |
| Auditor | Tanner LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $283K | -$6.3M | -$5.7M | $715K | No debt tags | $859K | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $166K | -$6.3M | -$7.2M | $3.6M | No debt tags | $721K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $146K | -$9.1M | -$7.8M | $8.2M | No debt tags | $718K | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $264K | -$25.7M | -$6.2M | $11.9M | No debt tags | $622K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $145K | -$5.9M | -$5.9M | $11.4M | No debt tags | $508K | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $163K | -$7.7M | -$8.3M | $11.1M | No debt tags | $1.0M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $50K | -$7.5M | -$8.7M | $1.9M | No debt tags | $3.5M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $149K | -$11.0M | -$8.2M | $2.9M | No debt tags | $3.9M | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-04 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-10-26 |
Source: SEC EDGAR submissions feed, 393 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | -75.7% |
| 3 months | -82.6% |
| Year to date | -94.9% |
| 1 year | -97.7% |
| From 52-week high | -97.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMIX | Autonomix Medical Inc. | $1.10 | -19.71% | $2.2M |
| BJDX | Bluejay Diagnostics Inc. | $2.29 | -12.26% | $2.6M |
| ICCM | IceCure Medical Ltd. | $0.7601 | +4.12% | $2.6M |
| IVF | INVO Fertility Inc. | $2.40 | -7.69% | $2.8M |
| VVOS | Vivos Therapeutics Inc. | $0.0822 | -16.12% | $2.8M |
| NXGL | NexGel Inc | $3.93 | +2.08% | $1.9M |
| XAIR | Beyond Air Inc. | $2.02 | -5.16% | $3.4M |
| TNON | Tenon Medical Inc. | $1.33 | -5.32% | $3.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier